BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
– At the highest dose level evaluated to date (Cohort 4, 0.128 mg/kg once daily),…
Saudi Arabia Hit 85% Digital: The Rails Under the Card Are Next
Creative Pass Studio Launches Unlimited Design Monthly Pass, Giving Agencies and Growing Businesses a Senior Creative Team Without Adding Headcount
Stardust Appoints Eamonn McHugh as CEO in Strategic Leadership Transition
SpeedyIndex Study Finds Only 3.7% of 15,389 Bought Backlinks Are in Google’s Index a Year Later
Canary Capital Launches the First U.S. Spot Staked INJ ETF (Ticker: INJC)